

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/036732 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
A61P 35/00 (2006.01)

D Alderley, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(21) International Application Number:
PCT/GB2006/003623

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:
29 September 2006 (29.09.2006)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/722,281 30 September 2005 (30.09.2005) US

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).
(72) Inventors; and
(75) Inventors/Applicants (for US only): ANDREWS, David [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). BARKER, Andrew, John [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). FINLAY, Maurice, Raymond [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). GREEN, Clive [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). JONES, Clifford [GB/GB]; AstraZeneca R &


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMIDAZO [1,2-A] PYRIDINE HAVING ANTI-CELL-PROLIFERATION ACTIVITY



(57) Abstract: Compounds of formula (I): which possess cell cycle inhibitory activity are described.

WO 2007/036732 A1

IMIDAZO [1, 2-A] PYRIDINE HAVING ANTI-CELL-PROLIFERATION ACTIVITY

The invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cell-proliferation (such as anti-cancer) activity and are therefore useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cell-proliferation effect in a warm-blooded animal such as man.

The cell cycle is fundamental to the survival, regulation and proliferation of cells and is highly regulated to ensure that each step progresses in a timely and orderly manner. The progression of cells through the cell cycle arises from the sequential activation and de-activation of several members of the cyclin-dependent kinase (CDK) family. The activation of CDKs is dependent on their interaction with a family of intracellular proteins called cyclins. Cyclins bind to CDKs and this association is essential for CDK activity within the cell. Different cyclins are expressed and degraded at different points in the cell cycle to ensure that activation and inactivation of CDKs occurs in the correct order for progression through the cell cycle.

Moreover, CDKs appear to be downstream of a number of oncogene signalling pathways. Deregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells.

Accordingly it has been recognised that an inhibitor of cell cycle kinases, particularly inhibitors of CDK1, CDK2, CDK4 and CDK6 (which operate at the G2/M, G1/S-S-G2/M and G1-S phases respectively) should be of value as an active inhibitor of cell proliferation, such as growth of mammalian cancer cells.


Tumour cells are also thought to be highly dependent on the continual transcriptional activity of RNA polymerase II to maintain appropriate levels of anti-apoptotic proteins and ensure tumour cell survival. CDK1, CDK7, CDK8 and CDK9 in particular are known to regulate the activity of RNA polymerase II through phosphorylation of the C-terminal domain of the protein. Thus, the inhibition of RNA polymerase II activity through inhibitors of these CDKs may contribute to a pro-apoptotic effect in tumour cells.

- 2 -

The inhibition of cell cycle kinases is expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, 5 atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

WO 01/14375 describes certain imidazopyridines that inhibit the effect of cell cycle kinases. WO 02/66480 describes certain imidazopyridines that are useful in the treatment of GSK3-related disorders. The present invention is based on the discovery that a novel group of 10 imidazopyridines inhibit the effects of cell cycle kinases, particularly CDK2, and thus possess anti-cell-proliferation properties. The compounds of the present invention are not specifically disclosed in the above applications and we have identified that these compounds may possess beneficial properties in terms of one or more of their pharmacological activity (particularly as compounds which inhibit CDK2) and / or pharmacokinetic, efficacious, metabolic and 15 toxicological profiles that make them particularly suitable for *in vivo* administration to a warm blooded animal, such as man.

Accordingly, the present invention provides a compound of formula (I):



20 wherein:

R¹ is selected from halo, amino, C₁₋₃alkyl, C₁₋₃alkoxy, N-(C₁₋₃alkyl)amino, N,N-(C₁₋₃alkyl)₂amino and a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom;

m is 0-4; wherein the values of R¹ may be the same or different;

25 **R²** is selected from hydrogen, halo, amino, C₁₋₃alkyl and C₁₋₃alkoxy;

R³ is hydrogen or halo;

R⁴ is hydrogen, ethynyl, halo, cyano, hydroxy, amino, mesyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl or methoxy;

- 3 -

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁶;

R⁵ is a substituent on carbon and is selected from halo, cyano, hydroxy,

5 trifluoromethoxy, amino, carboxy, carbamoyl, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkanoyl, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl and N,N-(C₁₋₆alkyl)₂sulphamoyl; wherein R⁵ independently may be optionally substituted on carbon by one or more R⁷; or R⁵ is -NHR⁸, -NR⁹R¹⁰ or -O-R¹¹;

10 n is 0-4; wherein the values of R⁵ may be the same or different;

R⁶ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, N-(C₁₋₆alkyl)carbamoyl and N,N-(C₁₋₆alkyl)carbamoyl; wherein R⁶ may be optionally substituted on carbon by one or more R¹²;

R⁸, R⁹, R¹⁰ and R¹¹ are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl,

15 C₁₋₄alkylsulphonyl, C₂₋₄alkenylsulphonyl, C₂₋₄alkynylsulphonyl, C₁₋₄alkoxycarbonyl, carbamoyl, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)carbamoyl, carbocyclyl and heterocyclyl; wherein R⁸, R⁹, R¹⁰ and R¹¹ may be independently optionally substituted on carbon by a group selected from R¹³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R¹⁴;

20 R¹³ is selected from halo, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C₁₋₃alkyl and C₁₋₃alkoxy;

R¹⁴ is selected from C₁₋₃alkyl, C₁₋₃alkanoyl, C₁₋₃alkylsulphonyl, C₁₋₃alkoxycarbonyl, carbamoyl, N-(C₁₋₃alkyl)carbamoyl and N,N-(C₁₋₃alkyl)carbamoyl; and

R⁷ and R¹² are independently selected from halo, cyano, hydroxy, trifluoromethoxy,

25 trifluoromethyl, amino, carboxy, carbamoyl, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylarnino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl, ethylsulphonyl, methoxycarbonyl,

30 ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl and N-methyl-N-ethylsulphamoyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

- 4 -

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₆alkyl" and "C₁₋₄alkyl" include methyl, ethyl, propyl, isopropyl and *t*-butyl. "C₁₋₃alkyl" includes methyl, ethyl, propyl and isopropyl. However, 5 references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals.

The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be 10 understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- 15 group can optionally be replaced by a -C(O)-, a ring nitrogen atom may optionally bear a C₁₋₆alkyl group and form a quaternary compound or a ring nitrogen and/or sulphur atom may be optionally oxidised to form the *N*-oxide and or the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, 20 pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, *N*-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, 25 pyridine-*N*-oxide and quinoline-*N*-oxide. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH₂- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.

A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH₂- group can optionally be replaced by a 30 -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetalinyl, indanyl or 1-oxoindanyl.

- 5 -

A “nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom” is a saturated monocyclic ring containing 4-7 atoms linked to formula (I) via a nitrogen atom contained in the ring, the ring optionally contains an additional heteroatom selected from nitrogen, sulphur or oxygen, wherein a -CH₂- group can optionally be replaced by a -C(O)-, and the optional sulphur atom may be optionally oxidised to form the S-oxides. A “nitrogen linked 5 or 6 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom” is defined as for a “nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom” but wherein the ring has only 5 or 6 atoms. Suitable values of a “nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom” include piperidinyl, morpholino, pyrrolidino and piperazinyl. A further suitable example is homopiperazinyl.

Examples of “C₁₋₆alkoxycarbonyl” and “C₁₋₄alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of “C₁₋₃alkoxycarbonyl” include methoxycarbonyl and ethoxycarbonyl. Examples of “C₁₋₃alkoxy” include methoxy, ethoxy and propoxy. Examples of “C₁₋₆alkylS(O)_a wherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of “C₁₋₆alkanoyl”, “C₁₋₄alkanoyl” and “C₁₋₃alkanoyl” include propionyl and acetyl. Examples of “C₂₋₆alkenyl” are vinyl, allyl and 1-propenyl. Examples of “C₂₋₆alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of “N-(C₁₋₆alkyl)sulphamoyl” are *N*-(methyl)sulphamoyl and *N*-(ethyl)sulphamoyl. Examples of “N,N-(C₁₋₆alkyl)₂sulphamoyl” are *N,N*-(dimethyl)sulphamoyl and *N*-(methyl)-*N*-(ethyl)sulphamoyl. Examples of “N-(C₁₋₆alkyl)carbamoyl”, “N-(C₁₋₄alkyl)carbamoyl” and “N-(C₁₋₃alkyl)carbamoyl” are methylaminocarbonyl and ethylaminocarbonyl. Examples of “N,N-(C₁₋₆alkyl)₂carbamoyl”, “N,N-(C₁₋₄alkyl)₂carbamoyl” and “N,N-(C₁₋₃alkyl)₂carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of “C₁₋₄alkylsulphonyl” and include methylsulphonyl, isopropylsulphonyl and *t*-butylsulphonyl. Examples of “C₁₋₃alkylsulphonyl” and include methylsulphonyl and isopropylsulphonyl. Examples of “C₁₋₄alkenylsulphonyl” include ethenylsulphonyl and allylsulphonyl. Examples of “C₁₋₄alkynylsulphonyl” include ethynylsulphonyl and propynylsulphonyl. Examples of “N-(C₁₋₃alkyl)amino” included methylamino and ethylamino. Examples of “N,N-(C₁₋₃alkyl)₂amino” include methylethylamino and dimethylamino.

- 6 -

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In 5 addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or 10 tris-(2-hydroxyethyl)amine.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, 15 C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

20 An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups 25 for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxy carbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl 30 ring.

Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention

encompasses all such optical, diastereoisomers and geometric isomers that possess CDK inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK inhibitory activity.

5 It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess CDK inhibitory activity.

10 Particular values of variable groups are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

m is 0.

R² is selected from hydrogen or C₁₋₃alkyl.

R² is selected from hydrogen or methyl.

15 R² is methyl.

R² is hydrogen.

R³ is hydrogen.

R³ is halo.

R³ is fluoro.

20 R⁴ is hydrogen, halo or methyl.

R⁴ is hydrogen, fluoro or methyl.

Ring A is a nitrogen linked 5-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁶; wherein R⁶ is C₁₋₆alkyl.

25 Ring A is a nitrogen linked 5 or 6 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁶; wherein R⁶ is C₁₋₆alkyl.

Ring A is pyrrolidin-1-yl, piperazin-1-yl, homopiperazin-1-yl or morpholino; wherein said piperazin-1-yl or homopiperazin-1-yl may be optionally substituted on nitrogen by R⁶; 30 wherein R⁶ is methyl or isopropyl.

Ring A is pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein said piperazin-1-yl may be optionally substituted on nitrogen by R⁶; wherein R⁶ is methyl.

- 8 -

Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl or 4-isopropylhomopiperazin-1-yl or morpholino.

Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl or morpholino.

R⁵ is a substituent on carbon and is selected from -NR⁹R¹⁰; wherein R⁹ and R¹⁰ are independently selected from C₁₋₄alkyl.

R⁵ is a substituent on carbon and is selected from -NR⁹R¹⁰; wherein R⁹ and R¹⁰ are independently selected from methyl.

R⁵ is a substituent on carbon and is dimethylamino.

n is 0.

10 n is 1.

n is 0 or 1.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

m is 0;

15 R² is selected from hydrogen or C₁₋₃alkyl;

R³ is hydrogen;

R⁴ is hydrogen, halo or methyl;

Ring A is a nitrogen linked 5-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if said ring contains an additional nitrogen atom 20 that nitrogen may be optionally substituted by R⁶; wherein R⁶ is C₁₋₆alkyl.

R⁵ is a substituent on carbon and is selected from -NR⁹R¹⁰; wherein R⁹ and R¹⁰ are independently selected from C₁₋₄alkyl;

n is 0 or 1;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

25 Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

m is 0;

R² is hydrogen;

R³ is hydrogen;

30 R⁴ is hydrogen, halo or methyl;

Ring A is a nitrogen linked 5 or 6 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁶; wherein R⁶ is C₁₋₆alkyl;

- 9 -

R⁵ is a substituent on carbon and is selected from -NR⁹R¹⁰; wherein R⁹ and R¹⁰ are independently selected from C₁₋₄alkyl;

n is 0 or 1;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

5 Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein

m is 0;

R² is selected from hydrogen or methyl;

R³ is hydrogen;

10 R⁴ is hydrogen, fluoro or methyl;

Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl or 4-isopropylhomopiperazin-1-yl or morpholino;

R⁵ is a substituent on carbon and is dimethylamino;

n is 0 or 1;

15 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein

m is 0;

R² is hydrogen;

20 R³ is hydrogen;

R⁴ is hydrogen, fluoro or methyl;

Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl or morpholino;

R⁵ is a substituent on carbon and is dimethylamino;

n is 0 or 1;

25 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.

30 Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:


- 10 -

Process a) reaction of a pyrimidine of formula (II):



(II)


wherein L is a displaceable group; with an aniline of formula (III):



(III)


or

Process b) reacting a compound of formula (IV):



(IV)

with a compound of formula (V):




(V)

wherein T is O or S; R^x may be the same or different and is selected from C₁₋₆alkyl; or


15 *Process c)* reacting an acid of formula (VI):

- 11 -



(VI)


or an activated acid derivative thereof; with an amine of formula (VII):



5 (VII)


or

Process d) for compounds of formula (I); reacting a pyrimidine of formula (VIII):



(VIII)

10 with a compound of formula (IX):



(IX)

where Y is a displaceable group;

and thereafter if necessary:

15 i) converting a compound of the formula (I) into another compound of the formula (I);
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

L is a displaceable group, suitable values for L are for example, a halogeno or

- 12 -

sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

Y is a displaceable group, suitable values for Y are for example, a halogeno or sulphonyloxy group, for example a bromo, iodo or trifluoromethanesulphonyloxy group.

5 Preferably Y is iodo.

Specific reaction conditions for the above reactions are as follows.

Process a) Pyrimidines of formula (II) and anilines of formula (III) may be reacted together:


i) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or *N*-methyl pyrrolidine, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or

ii) under standard Buchwald conditions (for example see *J. Am. Chem. Soc.*, **118**, 7215; *J. Am. Chem. Soc.*, **119**, 8451; *J. Org. Chem.*, **62**, 1568 and 6066) for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-*t*-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and at a temperature in the range of 25 to

20 80°C.

Pyrimidines of the formula (II) where L is chloro may be prepared according to

Scheme 1:




Scheme 1

- 13 -

Anilines of formula (III) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process b) Compounds of formula (IV) and compounds of formula (V) are reacted together in a suitable solvent such as *N*-methylpyrrolidinone or butanol at a temperature in the range of 100-200°C, preferably in the range of 150-170°C. The reaction is preferably conducted in the presence of a suitable base such as, for example, sodium hydride, sodium methoxide or potassium carbonate.

Compounds of formula (V) may be prepared according to *Scheme 2*:



10

Scheme 2

Compounds of formula (IV) and (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process c) Acids and amines may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for Example triethylamine, pyridine, or 2,6-di-*alkyl*-pyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of

- 14 -

compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

5 Compounds of formula (VI) may be prepared by adapting *Process a), b) or c)*.

Amines of formula (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process d) Compounds of formula (VIII) and amines of formula (IX) may be reacted together under standard Buchwald conditions as described in *Process a*.

10 The synthesis of compounds of formula (VIII) is described in *Scheme 1*.

Compounds of formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or

15 generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such

20 procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as

aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts

25 conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyloxy or alkylsulphonyloxy.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley

and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

- 16 -

As stated hereinbefore the compounds defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the CDK inhibitory activity of the compound. These properties may be assessed, for example, using the procedure set out below:-

5 **Assay**

The following abbreviations have been used :-

HEPES is *N*-[2-Hydroxyethyl]piperazine-*N'*-[2-ethanesulfonic acid]

DTT is Dithiothreitol

PMSF is Phenylmethylsulphonyl fluoride

10 The compounds were tested in an *in vitro* kinase assay in 96 well format using Scintillation Proximity Assay (SPA - obtained from Amersham) for measuring incorporation of [γ -33-P]-Adenosine Triphosphate into a test substrate (GST-Retinoblastoma protein; GST-Rb). In each well was placed the compound to be tested (diluted in DMSO and water to correct concentrations) and in control wells either roscovitine as an inhibitor control or
15 DMSO as a positive control.

Approximately 0.2 μ l of CDK2/Cyclin E partially-purified enzyme (amount dependent on enzyme activity) diluted in 25 μ l incubation buffer was added to each well then 20 μ l of GST-Rb/ATP/ATP33 mixture (containing 0.5 μ g GST-Rb and 0.2 μ M ATP and 0.14 μ Ci [γ -33-P]-Adenosine Triphosphate in incubation buffer), and the resulting mixture shaken gently,
20 then incubated at room temperature for 60 minutes.

To each well was then added 150 μ L stop solution containing (0.8mg/well of Protein A-PVT SPA bead (Amersham)), 20pM/well of Anti-Glutathione Transferase, Rabbit IgG (obtained from Molecular Probes), 61mM EDTA and 50mM HEPES pH 7.5 containing 0.05% sodium azide.

25 The plates were sealed with Topseal-S plate sealers, left for two hours then spun at 2500rpm, 1124xg., for 5 minutes. The plates were read on a Topcount for 30 seconds per well.

The incubation buffer used to dilute the enzyme and substrate mixes contained 50mM HEPES pH7.5, 10mM MnCl₂, 1mM DTT, 100 μ M Sodium vanadate, 100 μ M NaF, 10mM
30 Sodium Glycerophosphate, BSA (1mg/ml final).

Test substrate

In this assay only part of the retinoblastoma protein (Science 1987

Mar13;235(4794):1394-1399; Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., Lee

- 17 -

E.Y.) was used, fused to a GST tag. PCR of retinoblastoma gene encoding amino acids 379-928 (obtained from retinoblastoma plasmid ATCC pLRbRNL) was performed, and the sequence cloned into pGEx 2T fusion vector (Smith D.B. and Johnson, K.S. Gene 67, 31 (1988); which contained a tac promoter for inducible expression, internal lac I^q gene for use
5 in any E.Coli host, and a coding region for thrombin cleavage - obtained from Pharmacia Biotech) which was used to amplify amino acids 792-928. This sequence was again cloned into pGEx 2T.

The retinoblastoma 792-928 sequence so obtained was expressed in E.Coli (BL21 (DE3) pLysS cells) using standard inducible expression techniques, and purified as follows.

10 E.coli paste was resuspended in 10ml/g of NETN buffer (50mM Tris pH 7.5, 120mM NaCl, 1mM EDTA, 0.5%v/v NP-40, 1mM PMSF, 1ug/ml leupeptin, 1ug/ml aprotinin and 1ug/ml pepstatin) and sonicated for 2 x 45 seconds per 100ml homogenate. After centrifugation, the supernatant was loaded onto a 10ml glutathione Sepharose column (Pharmacia Biotech, Herts, UK), and washed with NETN buffer. After washing with kinase
15 buffer (50mM HEPES pH 7.5, 10mM MgCl₂, 1mM DTT, 1mM PMSF, 1ug/ml leupeptin, 1ug/ml aprotinin and 1ug/ml pepstatin) the protein was eluted with 50mM reduced glutathione in kinase buffer. Fractions containing GST-Rb(792-927) were pooled and dialysed overnight against kinase buffer. The final product was analysed by Sodium Dodeca Sulfate (SDS) PAGE (Polyacrylamide gel) using 8-16% Tris-Glycine gels (Novex, San
20 Diego, USA).

CDK2 and Cyclin E

The open reading frames of CDK2 and Cyclin E were isolated by reverse transcriptase-PCR using HeLa cell and activated T cell mRNA as a template and cloned into the insect expression vector pVL1393 (obtained from Invitrogen 1995 catalogue number:
25 V1392-20). CDK2 and cyclin E were then dually expressed [using a standard virus Baculogold co-infection technique] in the insect SF21 cell system (*Spodoptera Frugiperda* cells derived from ovarian tissue of the Fall Army Worm - commercially available).

Example production of Cyclin E/CDK2

The following Example provides details of the production of Cyclin E/CDK2 in SF21
30 cells (in TC100 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin E & CDK2.

- 18 -

SF21 cells grown in a roller bottle culture to 2.33×10^6 cells/ml were used to inoculate 10 x 500 ml roller bottles at 0.2×10^6 cells/ml. The roller bottles were incubated on a roller rig at 28°C.

After 3 days (72 hrs.) the cells were counted, and the average from 2 bottles found to 5 be 1.86×10^6 cells/ml. (99% viable). The cultures were then infected with the dual viruses at an MOI 3 for each virus.

The viruses were mixed together before addition to the cultures, and the cultures returned to the roller rig 28°C.

After 2 days (48 hrs.) post infection the 5 Litres of culture was harvested. The total 10 cell count at harvest was 1.58×10^6 cells/ml.(99% viable). The cells were spun out at 2500rpm, 30 mins., 4°C in Heraeus Omniprime 2.0 RS in 250 ml. lots. The supernatant was discarded.

Partial co-purification of Cdk2 and Cyclin E

Sf21 cells were resuspended in lysis buffer (50mM Tris pH 8.2, 10mM MgCl₂, 1mM 15 DTT, 10mM glycerophosphate, 0.1mM sodium orthovanadate, 0.1mM NaF, 1mM PMSF, 1ug/ml leupeptin and 1ug/ml aprotinin) and homogenised for 2 minutes in a 10ml Dounce homogeniser. After centrifugation, the supernatant was loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK). Cdk2 and Cyclin E were coeluted at the beginning of a 0-1M NaCl gradient (run in lysis buffer minus protease inhibitors) over 20 column volumes. Co-elution was checked by western blot using both anti-Cdk2 and anti-Cyclin E antibodies (Santa Cruz Biotechnology, California, US).

By analogy, assays designed to assess inhibition of CDK1 and CDK4 may be constructed. CDK2 (EMBL Accession No. X62071) may be used together with Cyclin A or Cyclin E (see EMBL Accession No. M73812), and further details for such assays are 25 contained in PCT International Publication No. WO99/21845, the relevant Biochemical & Biological Evaluation sections of which are hereby incorporated by reference.

Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC₅₀ concentrations or doses in the range 250μM to 1nM.

When tested in the above in-vitro assay the CDK2 inhibitory activity of Example 2 30 CDK2 enzyme 0.09 μM.

In vivo activity

The *in vivo* activity of the compounds of the present invention may be assessed by standard techniques, for example by measuring inhibition of cell growth and assessing cytotoxicity.

5 Inhibition of cell growth may be measured by staining cells with Sulforhodamine B (SRB), a fluorescent dye that stains proteins and therefore gives an estimation of amount of protein (i.e. cells) in a well (see Boyd, M.R.(1989) Status of the NCI preclinical antitumour drug discovery screen. *Prin. Prac Oncol* 10:1-12). Thus, the following details are provided of measuring inhibition of cell growth:-

10 Cells may be plated in appropriate medium in a volume of 100ml in 96 well plates; media may be Dulbecco's Modified Eagle media for MCF-7, SK-UT-1B and SK-UT-1. The cells may be allowed to attach overnight, then inhibitor compounds added at various concentrations in a maximum concentration of 1% DMSO (v/v). A control plate may be assayed to give a value for cells before dosing. Cells may be incubated at 37°C, (5% CO₂) for
15 three days.

At the end of three days TCA may be added to the plates to a final concentration of 16% (v/v). Plates may be incubated at 4°C for 1 hour, the supernatant removed and the plates washed in tap water. After drying, 100ml SRB dye (0.4% SRB in 1% acetic acid) may be added for 30 minutes at 37°C. Excess SRB may be removed and the plates washed in 1%
20 acetic acid. The SRB bound to protein may be solubilised in 10mM Tris pH7.5 and shaken for 30 minutes at room temperature. The ODs may be read at 540nm, and the concentration of inhibitor causing 50% inhibition of growth determined from a semi-log plot of inhibitor concentration versus absorbance. The concentration of compound that reduced the optical density to below that obtained when the cells were plated at the start of the experiment should
25 give the value for toxicity.

Typical IC₅₀ values for compounds of the invention when tested in the SRB assay should be in the range 1mM to 1nM.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a
30 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular,

intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

5 The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However
10 the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
15 defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their CDK
20 inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by CDK enzymes, i.e. the compounds may be used to produce a CDK inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition
25 of CDK enzymes, i.e. the compounds may be used to produce an anti-proliferative and potentially apoptotic effect mediated alone or in part by the inhibition of CDKs. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2 and entry into or progression through M phase by inhibition of CDK1. Apoptotic effects may also be envisaged through
30 down-regulation of RNA polymerase II activity by inhibition of CDK1, CDK7, CDK8 and in particular, CDK9. Such a compound of the invention is expected to possess a wide range of anti-cancer properties as CDKs have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian

cancer. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, prostate and pancreas. In 5 particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDKs, especially those tumours which 10 are significantly dependent on CDKs for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.

It is further expected that a compound of the present invention will possess activity against other cell-proliferation diseases in a wide range of other disease states including leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, 15 Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as 20 defined hereinbefore for use as a medicament.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory effect.

25 In one aspect of the invention, where a cell cycle inhibitory effect is referred to this refers to inhibition of CDK1. In a further aspect of the invention, this refers to inhibition of CDK2. In a further aspect of the invention, this refers to inhibition of CDK4. In a further aspect of the invention, this refers to inhibition of CDK5. In a further aspect of the invention, this refers to inhibition of CDK6. In a further aspect of the invention, this refers to inhibition 30 of CDK7. In a further aspect of the invention, this refers to inhibition of CDK8. In a further aspect of the invention, this refers to inhibition of CDK9.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as

defined hereinbefore in the manufacture of a medicament for use in the production of an anti-cell-proliferation effect.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a CDK2 inhibitory effect.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of cancer.

10 In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary.

15 According to a further feature of the invention, there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in the manufacture of a medicament for use in the treatment of cancer, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, 20 atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

In a further aspect of the invention there is provided a method of producing a cell cycle inhibitory effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a 25 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a method of producing an anti-cell-proliferation effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a 30 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a method of producing a CDK2 inhibitory effect, in a warm-blooded animal in need of such treatment, which comprises

administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a method of treating cancer, in a
5 warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a method of treating leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney,
10 prostate, bladder, pancreas, vulva, skin or ovary, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a method of treating cancer,
15 fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula
20 (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable
25 diluent or carrier.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use as a medicament.

30 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the production of a cell cycle inhibitory effect.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the production of an anti-cell-proliferation effect.

5 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the production of a CDK2 inhibitory effect.

10 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancer.

15 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the treatment of leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary.

20 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before and a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancer, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and 25 chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, in the production of a cell cycle inhibitory effect.

30 In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, in the production of an anti-cell-proliferation effect.

- 25 -

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, in the production of a CDK2 inhibitory effect.

5 In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, in the treatment of cancer.

In a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the treatment of leukaemia or lymphoid malignancies or cancer of the
10 breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary.

According to a further feature of the invention, there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined herein before in the treatment of cancer, fibroproliferative and
15 differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

20 Preventing cells from entering DNA synthesis by inhibition of essential S-phase initiating activities such as CDK2 initiation may also be useful in protecting normal cells of the body from toxicity of cycle-specific pharmaceutical agents. Inhibition of CDK2 or 4 will prevent progression into the cell cycle in normal cells which could limit the toxicity of cycle-specific pharmaceutical agents which act in S-phase, G2 or mitosis. Such protection may result in the prevention of hair loss normally associated with these agents.

25 Therefore in a further aspect of the invention there is provided a compound of formula (I) as defined above or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for use as a cell protective agent.

Therefore in a further aspect of the invention there is provided a compound of formula (I) as defined above or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof
30 for use in preventing hair loss arising from the treatment of malignant conditions with pharmaceutical agents.

Examples of pharmaceutical agents for treating malignant conditions that are known to cause hair loss include alkylating agents such as ifosfamide and cyclophosphamide;

antimetabolites such as methotrexate, 5-fluorouracil, gemcitabine and cytarabine; vinca alkaloids and analogues such as vincristine, vinblastine, vindesine, vinorelbine; taxanes such as paclitaxel and docetaxel; topoisomerase I inhibitors such as irinotecan and topotecan; cytotoxic antibiotics such as doxorubicin, daunorubicin, mitoxantrone, actinomycin-D and 5 mitomycin; and others such as etoposide and tretinoin.

In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, may be administered in association with a one or more of the above pharmaceutical agents. In this instance the compound of formula (I) may be administered by systemic or non systemic means. Particularly the compound of 10 formula (I) may be administered by non-systemic means, for example topical administration.

Therefore in an additional feature of the invention, there is provided a method of preventing hair loss during treatment for one or more malignant conditions with pharmaceutical agents, in a warm-blooded animal, such as man, which comprises administering to said animal an effective amount of a compound of formula (I), or a 15 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

In an additional feature of the invention, there is provided a method of preventing hair loss during treatment for one or more malignant conditions with pharmaceutical agents, in a warm-blooded animal, such as man, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or *in* 20 *vivo* hydrolysable ester thereof in simultaneous, sequential or separate administration with an effective amount of said pharmaceutical agent.

According to a further aspect of the invention there is provided a pharmaceutical composition for use in preventing hair loss arising from the treatment of malignant conditions with pharmaceutical agents which comprises a compound of formula (I), or a 25 pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, and said pharmaceutical agent, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, and a pharmaceutical agent for treating malignant conditions that 30 is known to cause hair loss.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, in a first unit dosage form;
- b) a pharmaceutical agent for treating malignant conditions that is known to cause hair loss; in a second unit dosage form; and

5 c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, in the manufacture of a medicament for the prevention of hair loss during treatment of malignant conditions with pharmaceutical agents.

10 According to a further aspect of the present invention there is provided a combination treatment for the prevention of hair loss comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of

15 a pharmaceutical agent for treatment of malignant conditions to a warm-blooded animal, such as man.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit

20 dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.

The CDK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of

25 medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:

30 (i) other cell cycle inhibitory agents that work by the same or different mechanisms from those defined hereinbefore;

 (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase

inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 α -dihydroreductase (for example finasteride), anti-invasion agents (for example

5 metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and

10 (iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example

15 cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotapec); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan). According to this aspect of the invention there is provided a

20 pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the

25 development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the

30 invention described herein also apply.

Examples

The invention will now be illustrated by the following non limiting examples in which, unless stated otherwise:

- 29 -

- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals;
- 5 4.5-30mmHg) with a bath temperature of up to 60°C;
- (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
- (iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
- 10 (v) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectral data;
- (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given 15 in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d₆) as solvent unless otherwise indicated;
- (viii) chemical symbols have their usual meanings; SI units and symbols are used;
- (ix) solvent ratios are given in volume:volume (v/v) terms; and
- 20 (x) mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected by electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported; and unless otherwise stated, the mass ion quoted is (MH)⁺;
- 25 (xi) unless stated otherwise compounds containing an asymmetrically substituted carbon and/or sulphur atom have not been resolved;
- (xii) where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those used in the previous example; and
- 30 (xvi) the following abbreviations have been used:

MeOH	methanol;
DCM	dichloromethane;
DMSO	dimethylsulphoxide;

- 30 -

	EDTA	ethylenediaminetetraacetic acid;
	HBTU	<i>O</i> -benzotriazol-1-yl- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate;
	DIPEA	<i>N,N</i> -diisopropylethylamine;
5	RPHPLC	reverse phase high performance liquid chromatography; and
	Xanthphos	9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene.

Example 1

[4-(4-Imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone

10 4-Imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamine (Bioorganic & Medicinal Chemistry Letters 2004, 14(9), 2245-2248) (0.20 g, 0.95 mmol), palladium acetate (9 mg, 0.038 mmol), Xanthphos (33 mg, 0.057 mmol), caesium carbonate (0.46 g, 1.4 mmol) and (4-iodo-phenyl)-morpholin-4-yl-methanone (Method 16a in WO 05/044814) (330 mg, 1.05 mmol) were added to dioxane (7 ml) under a inert atmosphere and heated at reflux for 6 hours. Purification on silica using 0-10% MeOH in DCM as eluent gave the title compound as a colourless foam. Further purification was achieved using RPHPLC to give a colourless foam (239 mg, 63%); ¹H NMR (400.132 MHz) 10.13 (d, 1H), 9.89 (s, 1H), 8.64 (s, 1H), 8.48 (d, 1H), 7.85 (d, 2H), 7.79 (d, 1H), 7.52 (t, 1H), 7.46 (d, 1H), 7.43 (d, 2H), 7.16 (t, 1H), 3.65 - 3.60 (m, 4H), 3.58 - 3.51 (m, 4H); MH⁺ 401.

15

20

Examples 2-17

The following compounds were prepared by the procedure of Example 1 using the appropriate starting materials.

Ex	Compound	NMR	M/z	SM
2	[4-(4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone	(400.132 MHz) 10.12 (d, 1H), 9.89 (s, 1H), 8.63 (s, 1H), 8.48 (d, 1H), 7.84 (d, 2H), 7.78 (d, 1H), 7.52 (t, 1H), 7.46 (d, 1H), 7.40 (d, 2H), 7.15 (t, 1H), 3.58 - 3.48 (m, 4H), 2.38 - 2.30 (m, 4H), 2.21 (s, 3H)	414	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Example 59 of WO 03/004472

- 31 -

Ex	Compound	NMR	M/z	SM
3	[4-(4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-(4-methyl-piperazin-1-yl)-methanone	(400.132 MHz) 10.09 (d, 1H), 9.73 (s, 1H), 8.62 (s, 1H), 8.46 (d, 1H), 7.77 (d, 1H), 7.66 (s, 1H), 7.62 (d, 1H), 7.50 (t, 1H), 7.42 (d, 1H), 7.13 - 7.09 (m, 2H), 3.71 - 3.62 (m, 2H), 3.25 - 3.17 (m, 2H), 2.41 - 2.31 (m, 2H), 2.27 - 2.24 (m, 5H), 2.19 (s, 3H)	428	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 1
4	[2-Fluoro-4-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone	(400.132 MHz) 10.10 (d, 1H), 10.05 (s, 1H), 8.63 (s, 1H), 8.50 (d, 1H), 7.92 (d, 1H), 7.78 (d, 1H), 7.55 - 7.48 (m, 3H), 7.34 (t, 1H), 7.15 (t, 1H), 3.68 - 3.60 (m, 2H), 3.33 - 3.27 (m, 2H), 2.41 - 2.23 (m, 4H), 2.20 (s, 3H)	432	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 2
5	[4-(4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-morpholin-4-yl-methanone	(400.132 MHz) 10.04 (d, 1H), 9.71 (s, 1H), 8.57 (s, 1H), 8.40 (d, 1H), 7.72 (d, 1H), 7.61 (s, 1H), 7.57 (d, 1H), 7.45 (t, 1H), 7.37 (d, 1H), 7.10 (d, 1H), 7.06 (t, 1H), 3.63 - 3.55 (m, 4H), 3.50 - 3.43 (m, 2H), 3.19 - 3.12 (m, 2H), 2.18 (s, 3H)	415	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 3

- 32 -

Ex	Compound	NMR	M/z	SM
6	[2-Fluoro-4-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone	(400.132 MHz) 10.07 (s, 1H), 10.04 (s, 1H), 8.60 (s, 1H), 8.46 (d, 1H), 7.88 (d, 1H), 7.73 (d, 1H), 7.49 - 7.45 (m, 3H), 7.32 (t, 1H), 7.11 (t, 1H), 3.61 - 3.56 (m, 4H), 3.53 - 3.47 (m, 2H), 3.28 - 3.24 (m, 2H)	419	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 4
7	((S)-3-Dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone	(400.132 MHz) 10.13 (d, 1H), 9.89 (s, 1H), 8.63 (s, 1H), 8.48 (d, 1H), 7.84 (d, 2H), 7.78 (d, 1H), 7.59 - 7.48 (m, 3H), 7.46 (d, 1H), 7.15 (t, 1H), 3.71 - 3.46 (m, 3H), 3.38 - 3.24 (m, 1H), 2.75 - 2.60 (m, 1H), 2.18 (s, 3H), 2.12 (s, 3H), 2.08 - 2.00 (m, 1H), 1.80 - 1.66 (m, 1H)	429	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 9
8	((S)-3-Dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone	(400.132 MHz) 10.11 (d, 1H), 10.05 (s, 1H), 8.65 (s, 1H), 8.52 (d, 1H), 7.95 - 7.90 (d of d, 1H), 7.79 (d, 1H), 7.55 - 7.50 (m, 3H), 7.42 - 7.36 (m, 1H), 7.17 (t, 1H), 3.75 - 3.61 (m, 1H), 3.48 - 3.14 (m, 3H under H ₂ O), 2.79 - 2.67 (m, 1H), 2.19 (s, 3H), 2.11 - 1.99 (m, 4H), 1.82 - 1.68 (m, 1H)	446	4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 5

- 33 -

Ex	Compound	NMR	M/z	SM
9	((S)-3-Dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone	(400.132 MHz) 10.10 (d, 1H), 9.71 (s, 1H), 8.62 (s, 1H), 8.47 (d, 1H), 7.78 (d, 1H), 7.67 - 7.60 (m, 2H), 7.51 (t, 1H), 7.43 (d, 1H), 7.19 (t, 1H), 7.13 (t, 1H), 3.78 - 3.63 (m, 1H), 3.47 - 3.00 (m, 3H under H ₂ O), 2.78 - 2.68 (m, 1H), 2.25 (d, 3H), 2.20 (s, 3H), 2.09 (s, 3H), 2.05 - 1.97 (m, 1H), 1.82 - 1.68 (m, 1H)	442	4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 6
10	((R)-3-Dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone	(400.132 MHz) 10.13 (d, 1H), 9.89 (s, 1H), 8.63 (s, 1H), 8.49 (d, 1H), 7.85 - 7.77 (m, 3H), 7.56 - 7.45 (m, 4H), 7.16 (t, 1H), 3.74 - 3.20 (m, 4H), 2.75 - 2.61 (m, 1H), 2.23 - 1.98 (m, 7H), 1.79 - 1.67 (m, 1H)	428	4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 10
11	((R)-3-Dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone	NMR (400.132 MHz) 10.12 (d, 1H), 10.06 (d, 1H), 8.65 (s, 1H), 8.52 (d, 1H), 7.95 - 7.91 (m, 1H), 7.80 (d, 1H), 7.55 - 7.50 (m, 3H), 7.42 - 7.37 (m, 1H), 7.18 (t, 1H), 3.75 - 3.61 (m, 1H), 3.48 - 3.34 (m, 2H), 3.24 - 3.14 (m, 1H), 2.77 - 2.67 (m, 1H), 2.19 (s, 3H), 2.11 - 1.99 (m, 4H), 1.82 - 1.67 (m, 1H)	447	4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 7

- 34 -

Ex	Compound	NMR	M/z	SM
12	((R)-3-Dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone	NMR (400.132 MHz) 10.10 (d, 1H), 9.72 (s, 1H), 8.62 (s, 1H), 8.47 (d, 1H), 7.78 (d, 1H), 7.67 - 7.60 (m, 2H), 7.51 (t, 1H), 7.43 (d, 1H), 7.19 (t, 1H), 7.13 (t, 1H), 3.77 - 3.63 (m, 1H), 3.47 - 3.00 (m, 3H), 2.71 (septet, 1H), 2.25 (d, 3H), 2.19 (s, 3H), 2.08 - 1.95 (m, 4H), 1.81 - 1.67 (m, 1H)	443	4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 8
13	[4-(4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-[4-methyl-[1,4]diazepan-1-yl]-methanone	NMR (499.803 MHz) 9.99 (d, 1H), 9.45 (s, 1H), 8.49 (s, 1H), 8.45 (d, 1H), 7.78 (d, 2H), 7.72 (d, 1H), 7.46 (t, 1H), 7.37 - 7.34 (m, 3H), 7.07 (t, 1H), 3.60 - 3.54 (m, 4H), 2.62 (t, 2H), 2.58 (t, 2H), 2.31 (s, 3H), 1.81 (quintet, 2H)	428	4-Imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamine ¹ and Method 11
14	{4-[4-(2-Methylimidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone	NMR (400.132 MHz) 9.87 (s, 1H), 9.78 (d, 1H), 8.57 (d, 1H), 7.84 (m, 2H), 7.65 (d, 1H), 7.45 (m, 1H), 7.37 (d, 2H), 7.16 (d, 1H), 7.04 (m, 1H), 3.52 (m, 4H), 2.67 (s, 3H), 2.33 (m, 4H), 2.21 (s, 3H)	428	4-(2-Methylimidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamine ¹ ; Example 59 of WO 03/004472

Ex	Compound	NMR	M/z	SM
15	(4-Methyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone	(499.803 MHz, 373K) 9.65 (d, 1H), 9.44 (s, 1H), 8.54 (d, 1H), 7.40 (m, 1H), 7.79 (m, 2H), 7.59 (d, 1H), 7.33 (d, 2H), 7.12 (d, 1H), 6.97 (t, 1H), 3.56 (m, 4H), 2.66 (s, 3H), 2.62 (m, 2H), 2.57 (m, 2H), 2.31 (s, 3H), 1.81 (m, 2H)	442	4-(2-Methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamine ¹ , Method 11
16	((S)-3-Dimethylamino-pyrrolidin-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone	(499.803 MHz, 373K) 9.65 (d, 1H), 9.47 (s, 1H), 8.54 (d, 1H), 7.81 (m, 2H), 7.59 (d, 1H), 7.48 (m, 2H), 7.40 (m, 1H), 7.13 (d, 1H), 6.97 (t, 1H), 3.59 - 3.68 (m, 2H), 3.50 (m, 1H), 3.34 (m, 1H), 2.84 (m, 1H), 2.67 (s, 3H), 2.21 (s, 6H), 2.04 (m, 1H), 1.79 (m, 1H)	442	4-(2-Methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamine ¹ ; Method 9
17	(4-Isopropyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone	(499.803 MHz, 373K) 9.65 (d, 1H) 9.43 (s, 1H), 8.53 (d, 1H), 7.79 (m, 2H), 7.59 (d, 1H), 7.32 (d, 2H), 7.40 (m, 1H), 7.12 (d, 1H), 6.96 (t, 1H), 3.54 (m, 4H), 2.88 (m, 1H), 2.62 - 2.70 (m, 7H), 1.73 (m, 2H), 0.98 (d, 6H)	470	4-(2-Methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamine ¹ ; Method 12

¹ Bioorganic & Medicinal Chemistry Letters 2004, 14(9), 2245-2248

Preparation of Starting Materials

Method 1

(4-Bromo-2-methyl-phenyl)-(4-methyl-piperazin-1-yl)-methanone

5 4-Bromo-2-methylbenzoic acid (10 g, 46.5 mmol), and HBTU (23 g, 60.5 mmol) were dissolved in DMF (150 mL), then *N*-methyl piperazine (6.0 g, 60.5 mmol) and DIPEA (21 mL, 121 mmol) were added. The reaction was stirred overnight before the removal of the DMF *in vacuo*, the gum was quenched with 2.0N NaOH (100 mL), extracted with diethyl ether (3 x 200 mL), dried (MgSO_4) and solvent removed in *vacuo* to yield a viscous gum.

10 Purification on silica using 0-10% MeOH in DCM as eluent, gave the title compound as viscous oil. The oil was dissolved in the minimum amount of diethyl ether, iso-hexane was added to give a colourless solid which was filtered and dried (11.8 g, 86%); ^1H NMR (CDCl_3) 7.40 (s, 1H), 7.36 (d, 1H), 7.04 (d, 1H), 3.86 - 3.79 (m, 2H), 3.27 - 3.21 (m, 2H), 2.51 - 2.45 (m, 2H), 2.32 - 2.29 (m, 8H); MH^+ 298.

15

Methods 2-8

Using the procedure described for Method 1 the following Methods 2-8 were prepared in a similar way.

Meth	Compound	NMR	M/z	SM
2	(4-Bromo-2-fluoro-phenyl)-(4-methyl-piperazin-1-yl)-methanone	(CDCl_3) 7.35 (d, 1H), 7.33 - 7.22 (m, 2H), 3.86 - 3.79 (m, 2H), 3.27 - 3.21 (m, 2H), 2.51 - 2.45 (m, 2H), 2.32 - 2.29 (m, 8H)	301	4-bromo-2-fluorobenzoic acid, <i>N</i> -methylpiperazine
3	(4-Bromo-2-methyl-phenyl)-morpholin-4-yl-methanone	(CDCl_3) 7.40 (s, 1H), 7.36 (d, 1H), 7.04 (d, 1H), 3.83 - 3.73 (m, 4H), 3.61 - 3.56 (m, 2H), 3.26 - 3.20 (m, 2H), 2.30 (s, 3H)	285	4-Bromo-2-methylbenzoic acid, morpholine
4	(4-Bromo-2-fluoro-phenyl)-morpholin-4-yl-methanone	(CDCl_3) 7.40 (d, 1H), 7.33 - 7.31 (m, 1H), 7.30 - 7.26 (m, 1H), 3.87 - 3.74 (m, 4H), 3.67 - 3.58 (m, 2H), 3.40 - 3.29 (m, 2H)	289	4-bromo-2-fluorobenzoic acid, morpholine

Meth	Compound	NMR	M/z	SM
5	(3 <i>S</i>)-1-(4-Bromo-2-fluorobenzoyl)- <i>N,N</i> -dimethylpyrrolidin-3-amine	(CDCl ₃) 7.38 - 7.27 (m, 3H), 3.98 - 3.81 (m, 1H), 3.63 - 3.17 (m, 3H), 2.85 - 2.68 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.19 - 2.04 (m, 1H), 1.92 - 1.77 (m, 1H)	316	(3 <i>S</i>)- <i>N,N</i> -dimethylpyrrolidin-3-amine and 4-bromo-2-fluorobenzoic acid
6	(3 <i>S</i>)-1-(4-Bromo-2-methylbenzoyl)- <i>N,N</i> -dimethylpyrrolidin-3-amine	(CDCl ₃) 7.39 (s, 1H), 7.35 (d, 1H), 7.06 (d, 1H), 4.00 - 3.84 (m, 1H), 3.61 - 3.35 (m, 1H), 3.31 - 3.23 (m, 1H), 3.18 - 2.95 (m, 1H), 2.80 - 2.63 (m, 1H), 2.29 (s, 6H), 2.19 - 2.03 (m, 4H), 1.90 - 1.74 (m, 1H); m/z 312.	312	(3 <i>S</i>)- <i>N,N</i> -dimethylpyrrolidin-3-amine and 4-bromo-2-methylbenzoic acid
7	(3 <i>R</i>)-1-(4-Bromo-2-fluorobenzoyl)- <i>N,N</i> -dimethylpyrrolidin-3-amine	(CDCl ₃) 7.38 - 7.27 (m, 3H), 3.97 - 3.81 (m, 1H), 3.63 - 3.17 (m, 3H), 2.84 - 2.68 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.17 - 2.02 (m, 1H), 1.90 - 1.77 (m, 1H)	316	(3 <i>R</i>)- <i>N,N</i> -dimethylpyrrolidin-3-amine and 4-bromo-2-fluorobenzoic acid
8	(3 <i>R</i>)-1-(4-Bromo-2-methylbenzoyl)- <i>N,N</i> -dimethylpyrrolidin-3-amine	300.072 MHz, (CDCl ₃) 7.39 (s, 1H), 7.35 (d, 1H), 7.07 (dd, 1H), 4.00 - 3.84 (m, 1H), 3.61 - 3.35 (m, 1H), 3.31 - 2.95 (m, 2H), 2.81 - 2.64 (m, 1H), 2.30 (s, 6H), 2.19 - 2.02 (m, 4H), 1.90 - 1.76 (m, 1H)	312	(3 <i>R</i>)- <i>N,N</i> -dimethylpyrrolidin-3-amine and 4-bromo-2-methylbenzoic acid

Method 9((S)-3-Dimethylamino-pyrrolidin-1-yl)-(4-iodo-phenyl)-methanone

4-Iodobenzoyl chloride (5 g, 0.019 mol) and triethylamine (6.6 ml, 0.048 mol) were added to DCM (100 ml) and cooled to 0°C. To this was slowly added (S)-dimethylamino-

pyrrolidine (2.2 g, 0.019 mol), the reaction was stirred for 1 hour then the solvent was removed *in vacuo* to 90% volume. The slurry obtained was quenched with 2.0 M NaOH (50 ml), extracted with diethyl ether (3 x 200 ml), dried (MgSO_4) and the solvent removed *in vacuo* to yield a yellow solid. Diethyl ether was added and the system was sonicated for 10 minutes and filtered to give the title compound as an off white solid (3.9 g, 60%); ^1H NMR (300.072 MHz, CDCl_3) 7.75 (d, 2H), 7.25 (d, 2H), 3.94 - 3.78 (m, 1H), 3.66 - 3.25 (m, 3H), 2.81 - 2.62 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.16 - 2.02 (m, 1H), 1.97 - 1.76 (m, 1H); MH^+ 345.

10 Methods 10-12

Using the procedure described for Method 9 the following Methods 10-12 were prepared in a similar way.

Meth	Compound	NMR	M/z	SM
10	((R)-3-Dimethylamino-pyrrolidin-1-yl)-(4-iodophenyl)-methanone	(CDCl_3) 7.75 (d, 2H), 7.25 (d, 2H), 3.94 - 3.78 (m, 1H), 3.66 - 3.25 (m, 3H), 2.81 - 2.62 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.16 - 2.02 (m, 1H), 1.97 - 1.76 (m, 1H);	345	4-iodobenzoyl chloride and (R)-dimethylamino pyrrolidine
11	1-(4-Iodobenzoyl)-4-methyl-1,4-diazepane	(CDCl_3) 7.79 (d, 2H), 7.18 (d, 2H), 3.84 - 3.79 (m, 2H), 3.54 - 3.52 (m, 1H), 3.48 (t, 1H), 2.79 - 2.77 (m, 1H), 2.70 - 2.66 (m, 1H), 2.62 - 2.55 (m, 2H), 2.45 (s, 3H), 2.07 - 2.00 (m, 1H), 1.91 - 1.84 (m, 1H)	345	N-methylhomopiperazine and 4-iodobenzoyl chloride
12	1-Benzoyl-4-isopropyl-1,4-diazepane	(CDCl_3) 7.74 (d, 2H), 7.13 (d, 2H), 3.75 - 3.72 (m, 2H), 3.40 (t, 2H), 2.96 - 2.84 (m, 1H), 2.79 - 2.77 (m, 1H), 2.67 (t, 1H), 2.62 - 2.56 (m, 2H), 1.92 - 1.87 (m, 1H), 1.71 - 1.67 (m, 1H), 1.03 - 0.97 (m, 6H)	373	1-isopropyl-1,4-diazepane (Method 13) and 4-iodobenzoyl chloride

Method 13**1-Isopropyl-1,4-diazepane**

tert-Butyl 1,4-diazepane-1-carboxylate (17 g) and acetone (10 g) were added to MeOH (150 mL) and stirred at 0°C for 20 mins. NaCNBH₃ (6.4 g) was slowly added over a 5 20-minute period keeping the temperature below 0°C. After complete addition the reaction was allowed to warm to ambient temperature and stirred for 56 hrs. The reaction was concentrated *in vacuo* to yield a yellow residue. This was quenched with water (100 mL), extracted with ether (3 x 100 mL), dried and the solvent removed *in vacuo* to yield a viscous clear oil (20 g). The oil was added to TFA (50 mL) and DCM (50 mL), the reaction was 10 stirred for 16 hrs before concentration *in vacuo*. The reaction was quenched with water (30 mL), to this was added potassium carbonate until the aqueous was fully saturated, this was then extracted with EtOAc (3 x 200 mL), dried and the solvent carefully removed *in vacuo* to yield the title compound as a yellow oil (5.2 g); NMR (400.132 MHz, CDCl₃) 2.94 - 2.86 (m, 5H), 2.68 - 2.63 (m, 4H), 1.74 - 1.68 (m, 2H), 1.01 (d, 6H).

15

Example 18

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof (hereafter compound X), for therapeutic or prophylactic use in humans:-

(a): Tablet I	mg/tablet
Compound X	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

20

25

- 40 -

(b): Tablet II	mg/tablet
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c): Tablet III	mg/tablet
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d): Capsule	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5

(e): Injection I	(50 mg/ml)
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	(to adjust pH to 7.6)
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

- 41 -

(f): Injection II	10 mg/ml
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%


(g): Injection III	(1mg/ml,buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

Note

The above formulations may be obtained by conventional procedures well known in
 5 the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

1. A compound of formula (I):



(I)

wherein:

R¹ is selected from halo, amino, C₁₋₃alkyl, C₁₋₃alkoxy, N-(C₁₋₃alkyl)amino, N,N-(C₁₋₃alkyl)₂amino and a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom;

10 m is 0-4; wherein the values of R¹ may be the same or different;

R² is selected from hydrogen, halo, amino, C₁₋₃alkyl and C₁₋₃alkoxy;

R³ is hydrogen or halo;

R⁴ is hydrogen, ethynyl, halo, cyano, hydroxy, amino, mesyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl or methoxy;

15 Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R⁶;

R⁵ is a substituent on carbon and is selected from halo, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl,

20 C₂₋₆alkynyl, C₁₋₆alkanoyl, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl and N,N-(C₁₋₆alkyl)₂sulphamoyl; wherein R⁵ independently may be optionally substituted on carbon by one or more R⁷; or R⁵ is -NHR⁸, -NR⁹R¹⁰ or -O-R¹¹;

n is 0-4; wherein the values of R⁵ may be the same or different;

25 R⁶ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, N-(C₁₋₆alkyl)carbamoyl and N,N-(C₁₋₆alkyl)carbamoyl; wherein R⁶ may be optionally substituted on carbon by one or more R¹²;

- 43 -

R^8 , R^9 , R^{10} and R^{11} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{2-4} alkenylsulphonyl, C_{2-4} alkynylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, $N-(C_{1-4}\text{alkyl})$ carbamoyl, $N,N-(C_{1-4}\text{alkyl})$ carbamoyl, carbocyclyl and heterocyclyl; wherein R^8 , R^9 , R^{10} and R^{11} may be independently optionally substituted on carbon by a group selected from R^{13} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{14} ;

5 R^{13} is selected from halo, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C_{1-3} alkyl and C_{1-3} alkoxy;

10 R^{14} is selected from C_{1-3} alkyl, C_{1-3} alkanoyl, C_{1-3} alkylsulphonyl, C_{1-3} alkoxycarbonyl, carbamoyl, $N-(C_{1-3}\text{alkyl})$ carbamoyl and $N,N-(C_{1-3}\text{alkyl})$ carbamoyl; and

15 R^7 and R^{12} are independently selected from halo, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino, acetylamino, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl, N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl and N -methyl- N -ethylsulphamoyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

20

2. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in claim 1, wherein m is 0.

25

3. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in claim 1 or claim 2 wherein R^2 is selected from hydrogen or C_{1-3} alkyl.

4. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-3 wherein R^3 is hydrogen.

30

5. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-4 wherein R^4 is hydrogen, halo or methyl.


- 44 -

6. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-5 wherein Ring A is a nitrogen linked 5-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if said ring contains an additional nitrogen atom that nitrogen may be
5 optionally substituted by R⁶; wherein R⁶ is C₁₋₆alkyl.

7. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-6 wherein R⁵ is a substituent on carbon and is selected from -NR⁹R¹⁰; wherein R⁹ and R¹⁰ are independently selected from
10 C₁₋₄alkyl.

8. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-7 wherein n is 0 or 1.

15 9. A compound of formula (I):



wherein

m is 0;

20 R² is selected from hydrogen or methyl;

R³ is hydrogen;

R⁴ is hydrogen, fluoro or methyl;

Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl or 4-isopropylhomopiperazin-1-yl or morpholino;


25 R⁵ is a substituent on carbon and is dimethylamino;

n is 0 or 1;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

- 45 -

10. A compound of formula (I):



selected from:

- 5 [4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
[4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
- 10 [4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
- 15 [2-fluoro-4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
[2-fluoro-4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
- 20 ((S)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
((S)-3-dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- 25 ((S)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone;
((R)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
((R)-3-dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- 30 ((R)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-*a*]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone;

- 46 -

[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-{(4-methyl-[1,4]diazepan-1-yl)-methanone;}

{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;

5 (4-methyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone;


((S)-3-dimethylamino-pyrrolidin-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone; and

(4-isopropyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone;


10 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

11. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in claim 1, which process comprises
15 of:

Process a) reaction of a pyrimidine of formula (II):



wherein L is a displaceable group; with an aniline of formula (III):




20

or


Process b) reacting a compound of formula (IV):

- 47 -




(IV)

with a compound of formula (V):




(V)

wherein T is O or S; R^x may be the same or different and is selected from C₁₋₆alkyl; or
Process c) reacting an acid of formula (VI):



(VI)

10 or an activated acid derivative thereof; with an amine of formula (VII):




(VII)


or

Process d) for compounds of formula (I); reacting a pyrimidine of formula (VIII):

- 48 -



with a compound of formula (IX):



where Y is a displaceable group;

and thereafter if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- 10 iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

12. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, and a pharmaceutically-acceptable diluent or carrier.

15

13. A compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, for use as a medicament.

14. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in*
20 *vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the production of an anti-cell-proliferation effect.

15. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in*
25 *vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the production of a CDK2 inhibitory effect.

- 49 -

16. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the treatment of cancer.

5 17. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the treatment of leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary.

10

18. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the treatment of cancer, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic

15 nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

20 19. A method of producing an anti-cell-proliferation effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10.

25 20. A method of producing a CDK2 inhibitory effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10.

21. A method of treating cancer, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10.

- 50 -

22. A method of treating leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10.

23. A method of treating cancer, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1-10.

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/003623

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D471/04 A61P35/00 A61K31/437

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/14375 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; THOMAS ANDREW PETER [GB]) 1 March 2001 (2001-03-01) page 1, line 27 - line 29 claim 1 -----	1, 15

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search 30 January 2007	Date of mailing of the international search report 06/02/2007
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Fanni, Stefano

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2006/003623

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 19–23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/003623

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0114375	A	01-03-2001	AR	031075 A1		10-09-2003
			AT	251623 T		15-10-2003
			AU	757639 B2		27-02-2003
			AU	6583300 A		19-03-2001
			BG	106383 A		30-09-2002
			BR	0013476 A		30-04-2002
			CA	2376293 A1		01-03-2001
			CN	1370163 A		18-09-2002
			CZ	20020617 A3		12-06-2002
			DE	60005850 D1		13-11-2003
			DE	60005850 T2		24-03-2005
			DK	1214318 T3		09-02-2004
			EE	200200080 A		16-06-2003
			EP	1214318 A1		19-06-2002
			ES	2208397 T3		16-06-2004
			HK	1045510 A1		19-03-2004
			HU	0202494 A2		28-10-2002
			JP	2003507478 T		25-02-2003
			MX	PA02001674 A		06-08-2002
			NO	20020832 A		12-04-2002
			NZ	516740 A		24-09-2004
			PL	364722 A1		13-12-2004
			PT	1214318 T		27-02-2004
			SK	2402002 A3		10-09-2002
			UA	73522 C2		17-06-2002
			US	6855719 B1		15-02-2005
			ZA	200200028 A		02-04-2003